




SYNVERO HEALTH INTRODUCTION 2026

NON-CONFIDENTIAL





SYNVERO HEALTH INC

We develop AI-driven digital health adherence solutions to coach and monitor inhaled therapies (> 45 M US patients with asthma, COPD).

ISSUE WE ADDRESS

Poor inhaler device technique is a common, challenging issue; leads to low drug delivery, poor disease control and costly care complications.

OUR SOLUTION

Synvero's digital health application is clinically validated and FDA listed as medical device. AI and technology protected by US, EU & Asian patents.


WHY WE ARE DIFFERENT ?

Compatible with >95% of inhaler devices, only requires a smartphone, enabling rapid deployment across health systems.

OUR PRODUCT PROMISE

Our App guides, monitors and coaches correct inhaler technique, at each inhalation, improving adherence quality and delivering better patient outcomes.

Adherence That Delivers !



SYNVERO FOUNDER TEAM

PROFOUND EXPERTISE IN RESPIRATORY DISEASE, DIGITAL HEALTH AND US MARKET ENTRY



Peter Shadday | CEO and Founder

- 30 years in US and international Healthcare leadership roles in commercial launch, strategy, sales & market access
- As CCO, supported Breath Therapeutics 2019 acquisition by Zambon (>\$500 M)
- Novartis, Gilead, Lundbeck, Vertex, Zambon-Breath Therapeutics, VisionHealth
- Yale University, ESCP (France)
- LI: [linkedin.com/in/petershadday](https://www.linkedin.com/in/petershadday)



Philipp Kroneberg | CTO and Founder

- Medical engineer with 20 years experience in the life science industry, including HealthTech, Digital Therapeutics, MedTech, and Pharma.
- Proven track record across leadership roles with a strong focus on development, innovation, and operational excellence.
- Co-Founder and Managing Director of VisionHealth.
- LI: <https://www.linkedin.com/in/philipp-kroneberg-22a94344/>



Marcus Irsfeld | CFO & Founder

- Diploma in business administration (University Münster/Germany) with over 35 years of experience in different industries
- Over 25 years experience in the life science industry, including VisionHealth
- Has supported several biotech and Medtech companies at different stages of maturity as CFO (private and public)
- Serial entrepreneur and investor in Medtech, diagnostics and digital health.
- LI: <https://www.linkedin.com/in/marcus-irsfeld-64b94b6/>



Simone Seiter, MD-PhD, MBA | Strategic Advisor & Founder

- Board certified dermatologist with clinical experience in Germany
- >25 years experience Life Sciences consulting as VP and partner Commercial Strategy/Launch Excellence (IQVIA, SKP)
- Biotech entrepreneur / co-founder of EU-based Ph3 rare disease oncology start-up, leading the commercial function
- Biotech Board member at French GT company preparing for launch; advisor to VCs on Biotech start up
- Strategic commercialization, launch and brand excellence, portfolio and lifecycle-management, including go-to-market strategies, P&MA strategies, product lifecycle strategies and orphan diseases
- LI: [linkedin.com/in/dr-simone-seiter-76009120](https://www.linkedin.com/in/dr-simone-seiter-76009120)



AI-driven digital adherence solutions
targeting inhaled therapy adherence for
better patient outcomes



US Delaware Inc., present in NC Research
Triangle and Munich

1/ THE PROBLEM: POOR RESPIRATORY ADHERENCE

OF AN ESTIMATED \$25 BILLION SPENT FOR INHALERS ANNUALLY, **\$5-7 BILLION IS WASTED DUE TO INHALER MISUSE**

Respiratory diseases have massive public health impact

45 million


people suffering from respiratory diseases in the US (asthma, COPD)

35-60%

of Medicaid, Medicare patients experience poor asthma or COPD symptom control

Treatments

- Inhaled therapies are the backbone of treatment
- While new therapies emerge, the inhaler devices have changed little over the years
- 24 Million CMS Patients (Medicaid, Medicare); \$15 Bn annual inhaled treatment costs



Respiratory adherence quality is a broad issue

Inhaler devices are often misused. Difficult challenge to address in real life

90%

patients do not perform their inhalation therapy correctly

50%

Increased risk of complications

50%

patients never receive training for their inhalers

67-90 %

clinicians cannot demo correct technique

Inhaler handling errors lead to:

- Poor symptom control, ER visits, hospitalizations,
- **50% increased risk of hospitalization**, emergency dept. visits
- \$30-40,000 for a hospitalization, \$40,000/yr escalation to biological therapies
- Avoidable increased health costs and resources

Source : WHO respiratory diseases report ; numerous clinical studies

- Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. 2017;3:Cd012286.

- Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50(10):1360-1374

- Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients. Int J Chron Obstruct Pulmon Dis. 2016;11:597-602.

- Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019 Mar 14;15:461 -472.

MDI: Metered Dose Inhaler,
SMI: Soft Mist Inhaler,
DPI: Dry Powder Inhaler

2/ OUR SOLUTION: KATA FOR RESPIRATORY ADHERENCE

AI TECHNOLOGY FOR INHALED THERAPIES, RESULTING IN BETTER INHALATION QUALITY AND CLINICAL OUTCOMES

Patient benefit: better inhaling, made easy

- **Software only**, no hardware needed, can be used without active WIFI connection
- **Adapts easily** to any MDI, DPI or SMI
- Kata uses **the camera and microphone** of any smartphone to operate. IP protected technology (US, EU, Asia patents).

For HCPs and payers: adherence quality redefined

- Trains, monitors and coaches inhalation adherence
- **FDA listed type I medical device**
- **Validated** in seven trials and usability pilots >300 patients, 2500 active users
- Extensive data handling and cybersecurity know-how




 Click DEMO VIDEO

3/ CLINICAL VALIDATION: KATA ENHANCES BENEFITS OF INHALED THERAPIES VALIDATED IN SEVEN CLINICAL TRIALS WITH MORE THAN 300 PATIENTS IN ASTHMA AND COPD

Inhalation error reductions


Errors reduced 100% over 90 days



* In person training, video, IFU



High long term adherence

Sustained adherence over 90 days



Improved asthma symptom control

Significant improvement of ACQ-5 $p=0.036$



showed a clinically relevant improvement after 2-4 weeks



THANK YOU

Contact info:

Contact@Synvero-health.com

